Role Of Shubhdeep Liv-Gud Pill In Fatty Liver (Yakrutdalyodara)

Not Applicable

Not yet recruiting

• Conditions: Fatty (change of) liver, not elsewhere classified,

• Registration Number: CTRI/2020/02/023410
• Lead Sponsor: Shubhdeep Ayurveda Medical College And Hospital

Brief Summary

In ayurveda there are 8 types of UDARA-ROGA have been described, in Ayurveda agnidosha and malavrudhi are resion of UDARA-ROGA. If there is suppresion of agni especially jatharagni, due to faulty life style, as a result of which dosha get accumulated in the kostha. This cause  vitiation of Pranavayu, Jatharagni, and Apanavayu. As liver play important  part of digestion, become enlarge due to vitiation of Agani and Dosha. Yakrutdalyodara developed due to vitiation of Kapha leads to mandagni caused by the continous intake of vidahi and abhishyandi aahara. The sign and symptoms of yakrutdalodara are closely related to Fatty liver. According to line of treatment of Yakrutdalyodara the SHUBHDEEP LIV-GUD PILL is selected. Its prepration have been reported to possess liver protection effect. This study is carried out in one group with pre -test and post -test design where in a minimum 30 patient suffering from Yakrutdalyodara of either sex between the age group of 20 - 60  years will be selected for the study. Final assessment of result is made on the basis of subjective & objective criteria. Appropriate statistical tests will applied.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-02-17
• Study Start: 2020-02-19

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patient presenting with clinical feature of yakrutdalyodara(Fatty liver).
• Patient with or without the clinical feature of yakrutdalyodara, diagnosed to be having USG whole abdomen where include for the study.
• Patient age between 20-60 years with either sex.
• Patient of alcoholic addiction, obesity, type-2 diabetes mellitus.

Exclusion Criteria

• Patient aged less than 20 yr and more than 60 years.
• Patient with hepatic encephalopathy, systemic multiorgan syndrom, malignency of liver and cirrhosis of liver and prehepatic and hepatic coma, bleeding disorder, etc.
• Pregnent women.
• Hepatitis B and C.
• Patient on steroid treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Improve power of digestion.	45th day.
4) Relief in weakness.	45th day.
5) Relief in fever.	45th day.
6) Relief in constipation.	45th day.
2) Relief in anorexia.	45th day.
3) Relief in indigestion.	45th day.

Trial Locations

Locations (1)

OPD of kayachikitsa room no G-10 Shubhdeep ayurved medical college and hospital; 🇮🇳 Indore, MADHYA PRADESH, India

OPD of kayachikitsa room no G-10 Shubhdeep ayurved medical college and hospital

🇮🇳Indore, MADHYA PRADESH, India

Dr Ajit kumar shrivastava

Principal investigator

9074676268

dr.ajitshrivastava@gmail.com